What is NVA237 200 µg used for?

NVA237 200 µg is indicated for Chronic obstructive pulmonary disease (COPD).

Who makes NVA237 200 µg?

NVA237 200 µg is developed by Novartis.

What are the side effects of NVA237 200 µg?

Common side effects include Dry mouth, Headache.

Last reviewed 2026-04-23 · How we verify

NVA237 200 µg

Novartis · Phase 2 active Small molecule

NVA237 is a long-acting muscarinic antagonist that blocks the M3 muscarinic acetylcholine receptor in the airways, leading to bronchodilation.

NVA237 is a long-acting muscarinic antagonist that blocks the M3 muscarinic acetylcholine receptor in the airways, leading to bronchodilation. Used for Chronic obstructive pulmonary disease (COPD).

At a glance

Generic name	NVA237 200 µg
Also known as	Glycopyrronium Bromide
Sponsor	Novartis
Drug class	Muscarinic antagonist
Target	M3 muscarinic acetylcholine receptor
Modality	Small molecule
Therapeutic area	Respiratory
Phase	Phase 2

Mechanism of action

By blocking the M3 receptors, NVA237 reduces the constriction of the airways, which is beneficial in conditions such as chronic obstructive pulmonary disease (COPD).

Approved indications

Chronic obstructive pulmonary disease (COPD)

Common side effects

Dry mouth
Headache

Key clinical trials

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NVA237 200 µg CI brief — competitive landscape report
NVA237 200 µg updates RSS · CI watch RSS
Novartis portfolio CI